Key result
In patients with atrial fibrillation and cancer, NOACs decreased the risk of stroke or systemic embolism compared with warfarin (RR 0.52; 95% CI 0.28-0.99).
Why the study?
Several studies have investigated the effect of NOACs in AF patients with cancer, but the results remain controversial.
Do NOACs reduce thromboembolic and bleeding events compared to warfarin in patients with atrial fibrillation and cancer?
Comparison
NOACs vs warfarin
Design
Systematic review and meta-analysis
Authors
Loading...
NOACs may reduce mortality versus warfarin in AF with cancer; extends observational evidence but leaves practice change to RCTs.
Meta-Analysis (n=21,348)
Do NOACs reduce thromboembolic and bleeding events compared to warfarin in patients with atrial fibrillation and cancer?
Relative Risk: 0.52 (95% CI 0.28–0.99)
In patients with atrial fibrillation and cancer, NOACs are associated with lower risks of stroke, systemic embolism, venous thromboembolism, and specific bleeding events compared to warfarin.
Deng et al. (2019) conducted a meta-analysis in Atrial fibrillation and cancer (n=21,348). Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Warfarin was evaluated on Stroke or systemic embolism (RR 0.52, 95% CI 0.28-0.99). In patients with atrial fibrillation and cancer, NOACs decreased the risk of stroke or systemic embolism compared with warfarin (RR 0.52; 95% CI 0.28-0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: